Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27

Reuters

05/02

Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27

Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug $(IND.AU)$ filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532833714"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532833714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532833714?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532833714","market":"nz","top_or_hot":-1,"title":"Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-02 04:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STTK","symbol_name":"Shattuck Labs, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL92DSMW:1","article_id":"2532833714","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532833714","pubTimestamp":1746131280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug  filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber prese","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"STTK":"Shattuck Labs, Inc.","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Shattuck Labs报告2025年第一季度：净亏损收窄至1,370万美元，每股收益改善至0.27美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"STTK":0.9},"content_text":"Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    \n\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug $(IND.AU)$ filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}